IntelGenx Technologies Company Description
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market.
It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health.
It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression.
The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Dwight Gorham |
Contact Details
Address: 6420 Abrams Montreal, Delaware H4S 1Y2 Canada | |
| Phone | 514 331 7440 |
| Website | intelgenx.com |
Stock Details
| Ticker Symbol | IGXT |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US45822R1014 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dwight Gorham | Chief Executive Officer |
| André Godin | Chief Financial Officer |
| Stephen Kilmer | Head of Investor Relations |